Gut microbiota and its metabolite trimethylamine-N-oxide (TMAO): a novel regulator in coronary artery disease.

Yameng LI; Meize CUI; Jing SUN; Qiuyang WEI; Mingyu LIU; Jianwei ZHANG; Hongxiang QI; Lili ZHAO; Hui FANG; Zaihao CHEN; Shaojun LÜ

Return

Gut microbiota and its metabolite trimethylamine-N-oxide (TMAO): a novel regulator in coronary artery disease.

Author: Yameng LI ¹ ; Meize CUI ¹ ; Jing SUN ² ; Qiuyang WEI ¹ ; Mingyu LIU ¹ ; Jianwei ZHANG ¹ ; Hongxiang QI ² ; Lili ZHAO ² ; Hui FANG ¹ ; Zaihao CHEN ¹ ; Shaojun LÜ ¹
Author Information

1. College of Physical Education and Sports, Beijing Normal University, Beijing 100875, China.
2. Zibo Bashan Wanjie Hospital, Zibo 255000, Shandong, China.
Publication Type:Review
Keywords: coronary artery disease; gut microbiota; microbiota-derived metabolites; trimethylamine-N-oxide
MeSH: Coronary Artery Disease; Gastrointestinal Microbiome; Humans; Methylamines; Oxides
From: Chinese Journal of Biotechnology 2021;37(11):3745-3756
CountryChina
Language:Chinese
Abstract: Coronary artery disease (CAD) is a chronic disease but causes the highest mortality and morbidity among the cardiovascular diseases worldwide. Correlations between CAD and gut microbiota have been observed. This suggests that the gut microbiota could become a vital diagnostic marker of CAD, and restoring the gut habitat may become a promising strategy for CAD therapy. The elevated level of trimethylamine-N-oxide (TMAO), a gut microbiota-derived metabolite, was found to be associated with the increased risk of cardiovascular disease and the all-cause mortality. Preclinical studies have shown that it has pro-arteriosclerosis properties. It is likely that regulating the production of TMAO by gut microbiota may become a promising strategy for anti-atherosclerosis therapy. This review summarizes the clinical and preclinical researches on the intervention of CAD by regulating the gut microbiota and the microbiota-derived metabolite TMAO, with the aim to provide new target for the therapy of CAD.